Using the expected survival to explain differences between the results of randomized trials: A case in advanced ovarian cancer

Marc Buyse, Tomasz Burzykowski, Mahesh Parmar, Valter Torri, George Omura, Nicoletta Colombo, Chris Williams, Pierfranco Conte, Jan Vermorken

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Purpose: A meta-analysis of randomized trials in advanced ovarian cancer showed a longer survival with cyclophosphamide, doxorubicin, and cisplatin (CAP) than with cyclophosphamide and cisplatin (CP; P = .009). In contrast, the results of the large International Collaborative Ovarian Neoplasm Study (ICON2) showed no survival difference between CAP and carboplatin (P = .98). In this article, we show how these discrepant results can be reconciled through the estimation of expected survival curves. Materials and Methods: A proportional hazards model, fitted to the meta-analysis data, was used to construct the expected survival curve for each treatment arm of the ICON2 trial. Expected survival curves were compared with observed survival curves in the ICON2 trial at all time points using a nonparametric test. Results: The prognostic model for survival obtained in the meta-analysis included extent of residual disease, age. histologic grade, and International Federation of Gynecology and Obstetrics stage. When this model was applied to the ICON2 data, there was no difference between the expected and observed curves in the CAP arm. In contrast, the observed survival curve for carboplatin was far superior to the expected survival curve for CP (P <.01). Conclusion: These analyses provide indirect evidence that better results are achieved with carboplatin alone at an optimally tolerated dose, compared with the CP combination at a cisplatin dose of 50 to 60 mg/m2. The expected survival may provide valuable insight when direct comparisons between randomized groups yield discrepant results across different studies.

Original languageEnglish
Pages (from-to)1682-1687
Number of pages6
JournalJournal of Clinical Oncology
Volume21
Issue number9
DOIs
Publication statusPublished - May 1 2003

Fingerprint

Carboplatin
Ovarian Neoplasms
Cisplatin
Meta-Analysis
Cyclophosphamide
Gynecology
Proportional Hazards Models
Doxorubicin
Obstetrics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Using the expected survival to explain differences between the results of randomized trials : A case in advanced ovarian cancer. / Buyse, Marc; Burzykowski, Tomasz; Parmar, Mahesh; Torri, Valter; Omura, George; Colombo, Nicoletta; Williams, Chris; Conte, Pierfranco; Vermorken, Jan.

In: Journal of Clinical Oncology, Vol. 21, No. 9, 01.05.2003, p. 1682-1687.

Research output: Contribution to journalArticle

Buyse, Marc ; Burzykowski, Tomasz ; Parmar, Mahesh ; Torri, Valter ; Omura, George ; Colombo, Nicoletta ; Williams, Chris ; Conte, Pierfranco ; Vermorken, Jan. / Using the expected survival to explain differences between the results of randomized trials : A case in advanced ovarian cancer. In: Journal of Clinical Oncology. 2003 ; Vol. 21, No. 9. pp. 1682-1687.
@article{00ddb377ce8549a1a6740fe27a10c103,
title = "Using the expected survival to explain differences between the results of randomized trials: A case in advanced ovarian cancer",
abstract = "Purpose: A meta-analysis of randomized trials in advanced ovarian cancer showed a longer survival with cyclophosphamide, doxorubicin, and cisplatin (CAP) than with cyclophosphamide and cisplatin (CP; P = .009). In contrast, the results of the large International Collaborative Ovarian Neoplasm Study (ICON2) showed no survival difference between CAP and carboplatin (P = .98). In this article, we show how these discrepant results can be reconciled through the estimation of expected survival curves. Materials and Methods: A proportional hazards model, fitted to the meta-analysis data, was used to construct the expected survival curve for each treatment arm of the ICON2 trial. Expected survival curves were compared with observed survival curves in the ICON2 trial at all time points using a nonparametric test. Results: The prognostic model for survival obtained in the meta-analysis included extent of residual disease, age. histologic grade, and International Federation of Gynecology and Obstetrics stage. When this model was applied to the ICON2 data, there was no difference between the expected and observed curves in the CAP arm. In contrast, the observed survival curve for carboplatin was far superior to the expected survival curve for CP (P <.01). Conclusion: These analyses provide indirect evidence that better results are achieved with carboplatin alone at an optimally tolerated dose, compared with the CP combination at a cisplatin dose of 50 to 60 mg/m2. The expected survival may provide valuable insight when direct comparisons between randomized groups yield discrepant results across different studies.",
author = "Marc Buyse and Tomasz Burzykowski and Mahesh Parmar and Valter Torri and George Omura and Nicoletta Colombo and Chris Williams and Pierfranco Conte and Jan Vermorken",
year = "2003",
month = "5",
day = "1",
doi = "10.1200/JCO.2003.04.088",
language = "English",
volume = "21",
pages = "1682--1687",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "9",

}

TY - JOUR

T1 - Using the expected survival to explain differences between the results of randomized trials

T2 - A case in advanced ovarian cancer

AU - Buyse, Marc

AU - Burzykowski, Tomasz

AU - Parmar, Mahesh

AU - Torri, Valter

AU - Omura, George

AU - Colombo, Nicoletta

AU - Williams, Chris

AU - Conte, Pierfranco

AU - Vermorken, Jan

PY - 2003/5/1

Y1 - 2003/5/1

N2 - Purpose: A meta-analysis of randomized trials in advanced ovarian cancer showed a longer survival with cyclophosphamide, doxorubicin, and cisplatin (CAP) than with cyclophosphamide and cisplatin (CP; P = .009). In contrast, the results of the large International Collaborative Ovarian Neoplasm Study (ICON2) showed no survival difference between CAP and carboplatin (P = .98). In this article, we show how these discrepant results can be reconciled through the estimation of expected survival curves. Materials and Methods: A proportional hazards model, fitted to the meta-analysis data, was used to construct the expected survival curve for each treatment arm of the ICON2 trial. Expected survival curves were compared with observed survival curves in the ICON2 trial at all time points using a nonparametric test. Results: The prognostic model for survival obtained in the meta-analysis included extent of residual disease, age. histologic grade, and International Federation of Gynecology and Obstetrics stage. When this model was applied to the ICON2 data, there was no difference between the expected and observed curves in the CAP arm. In contrast, the observed survival curve for carboplatin was far superior to the expected survival curve for CP (P <.01). Conclusion: These analyses provide indirect evidence that better results are achieved with carboplatin alone at an optimally tolerated dose, compared with the CP combination at a cisplatin dose of 50 to 60 mg/m2. The expected survival may provide valuable insight when direct comparisons between randomized groups yield discrepant results across different studies.

AB - Purpose: A meta-analysis of randomized trials in advanced ovarian cancer showed a longer survival with cyclophosphamide, doxorubicin, and cisplatin (CAP) than with cyclophosphamide and cisplatin (CP; P = .009). In contrast, the results of the large International Collaborative Ovarian Neoplasm Study (ICON2) showed no survival difference between CAP and carboplatin (P = .98). In this article, we show how these discrepant results can be reconciled through the estimation of expected survival curves. Materials and Methods: A proportional hazards model, fitted to the meta-analysis data, was used to construct the expected survival curve for each treatment arm of the ICON2 trial. Expected survival curves were compared with observed survival curves in the ICON2 trial at all time points using a nonparametric test. Results: The prognostic model for survival obtained in the meta-analysis included extent of residual disease, age. histologic grade, and International Federation of Gynecology and Obstetrics stage. When this model was applied to the ICON2 data, there was no difference between the expected and observed curves in the CAP arm. In contrast, the observed survival curve for carboplatin was far superior to the expected survival curve for CP (P <.01). Conclusion: These analyses provide indirect evidence that better results are achieved with carboplatin alone at an optimally tolerated dose, compared with the CP combination at a cisplatin dose of 50 to 60 mg/m2. The expected survival may provide valuable insight when direct comparisons between randomized groups yield discrepant results across different studies.

UR - http://www.scopus.com/inward/record.url?scp=0038811780&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038811780&partnerID=8YFLogxK

U2 - 10.1200/JCO.2003.04.088

DO - 10.1200/JCO.2003.04.088

M3 - Article

C2 - 12721242

AN - SCOPUS:0038811780

VL - 21

SP - 1682

EP - 1687

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 9

ER -